Rezolute (NASDAQ:RZLT - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 446.88% from the company's current price.
RZLT has been the subject of several other research reports. Maxim Group began coverage on shares of Rezolute in a research report on Tuesday, April 9th. They set a "buy" rating and a $8.00 price target for the company. JMP Securities restated a "market outperform" rating and issued a $7.00 price objective on shares of Rezolute in a report on Thursday, April 18th. Finally, Jonestrading initiated coverage on shares of Rezolute in a report on Thursday, April 18th. They issued a "buy" rating and a $10.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $8.80.
Check Out Our Latest Analysis on RZLT
Rezolute Stock Down 3.4 %
NASDAQ:RZLT traded down $0.09 during trading hours on Thursday, hitting $2.56. 249,361 shares of the company's stock traded hands, compared to its average volume of 295,696. Rezolute has a 52 week low of $0.72 and a 52 week high of $3.69. The business's fifty day simple moving average is $2.54 and its two-hundred day simple moving average is $1.57. The firm has a market cap of $102.73 million, a P/E ratio of -2.33 and a beta of 1.29.
Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.27). On average, analysts expect that Rezolute will post -1.12 EPS for the current year.
Insider Buying and Selling
In related news, Director Young-Jin Kim bought 36,503 shares of the company's stock in a transaction on Thursday, March 7th. The shares were acquired at an average cost of $1.91 per share, with a total value of $69,720.73. Following the completion of the acquisition, the director now owns 115,450 shares of the company's stock, valued at approximately $220,509.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Young-Jin Kim bought 36,503 shares of the firm's stock in a transaction on Thursday, March 7th. The stock was acquired at an average cost of $1.91 per share, with a total value of $69,720.73. Following the completion of the acquisition, the director now owns 115,450 shares of the company's stock, valued at $220,509.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Daron Evans purchased 20,000 shares of the business's stock in a transaction dated Friday, March 15th. The shares were purchased at an average price of $1.69 per share, for a total transaction of $33,800.00. Following the acquisition, the chief financial officer now owns 20,000 shares of the company's stock, valued at $33,800. The disclosure for this purchase can be found here. Insiders have purchased 179,403 shares of company stock worth $306,601 in the last 90 days. Insiders own 20.80% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of RZLT. Affinity Asset Advisors LLC bought a new stake in Rezolute during the 1st quarter worth approximately $4,080,000. Acadian Asset Management LLC bought a new position in shares of Rezolute in the first quarter worth about $229,000. Vanguard Group Inc. grew its position in shares of Rezolute by 10.4% during the first quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company's stock worth $3,961,000 after purchasing an additional 145,700 shares in the last quarter. Rosalind Advisors Inc. purchased a new position in Rezolute in the 1st quarter worth approximately $510,000. Finally, Vivo Capital LLC boosted its stake in Rezolute by 569.4% in the 4th quarter. Vivo Capital LLC now owns 3,242,842 shares of the company's stock worth $3,219,000 after purchasing an additional 2,758,403 shares during the period. 82.97% of the stock is owned by institutional investors.
Rezolute Company Profile
(
Get Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
See Also
Before you consider Rezolute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.
While Rezolute currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
